Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Bispecific antibodies in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJohn R. Hartman

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows healthcare resource utilization in multiple myeloma patients treated with bispecific antibodies, indicating significant inpatient needs.

Key Points

  • This research aims to analyze patient characteristics and healthcare resource utilization related to bispecific antibodies in multiple myeloma treatment.
  • Retrospective cohort study using IQVIA database
  • Included adults with multiple myeloma from FDA-approval dates of treatments
  • Evaluated administration-related and post-administration healthcare resource utilization over specified periods
  • 405 patients treated with teclistamab, 78 with talquetamab, and 26 with elranatamab were observed
  • High rates of inpatient admissions related to hypogammaglobulinemia and hypertension in the post-treatment period
  • Intravenous immunoglobulin use was reported for a significant percentage of patients before and after treatment

Cite This Study

John R. Hartman (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da6ahttps://doi.org/10.1182/blood-2025-2790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma2026
  2. 2Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025
  3. 3Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).2026 · 1 citations
  4. 4Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs2025
  5. 5Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma.2024 · 4 citations